<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04180215</url>
  </required_header>
  <id_info>
    <org_study_id>H-200-001</org_study_id>
    <secondary_id>2019-000907-34</secondary_id>
    <nct_id>NCT04180215</nct_id>
  </id_info>
  <brief_title>A Study of TheraT® Vector(s) Expressing HPV 16+ in Patients With HPV 16+ Confirmed Cancers</brief_title>
  <official_title>A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients With HPV 16+ Confirmed Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hookipa Biotech GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hookipa Biotech GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an First in Human (FIH) Phase I/II, multinational, multicenter, open-label study of&#xD;
      HB-201 single vector therapy and HB-201 &amp; HB-202 two-vector therapy in patients with HPV 16+&#xD;
      confirmed cancers comprising two parts: Phase I Dose Escalation and Phase II Dose Expansion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HB-201 and HB-202 are 'vectors', modified viruses intended to train the body to recognize&#xD;
      antigens found in HPV 16+ cancer.&#xD;
&#xD;
      Phase I Dose Escalation will comprise three treatment groups evaluating HB-201 single vector&#xD;
      therapy (Groups 1, 2 and 5) and three treatment groups evaluating HB-201 &amp; HB-202 two-vector&#xD;
      therapy (Groups 3, 4 and 6). Group 1 and Group 2 Phase I Dose Escalation will determine a&#xD;
      safe recommended Phase II dose of HB-201. Group 3 and Group 4 Phase I Dose Escalation will&#xD;
      determine a safe RP2D of HB-202. Various doses of the investigational therapies (HB-201 and&#xD;
      HB-202) and dosing schedules may be evaluated in separate groups of patients (cohorts) during&#xD;
      Phase I Dose Escalation. Initial cohorts of HB-201 and/or HB-202 in combination with a&#xD;
      checkpoint inhibitor may also be evaluated during Phase I Dose Escalation.&#xD;
&#xD;
      Phase II Dose Expansion may have up to six treatment groups (Groups A to F) with HB-201 and&#xD;
      HB-202 administered at the recommended Phase II doses and the dosing schedule determined&#xD;
      during Phase I Dose Escalation. Potential groups will explore the following treatments:&#xD;
      HB-201 single vector therapy; HB-201 &amp; HB-202 two-vector therapy; HB-201 single vector&#xD;
      therapy in combination with an immune checkpoint inhibitor; and/or HB-201 &amp; HB-202 two-vector&#xD;
      in combination with an immune checkpoint inhibitor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I Dose Escalation: Determine Phase II dose based on incidence of dose-limiting toxicities.</measure>
    <time_frame>From dosing until 21-28 days after first dose</time_frame>
    <description>Determine the recommended Phase II dose in terms of safety and tolerability for intravenously administered HB-201, intratumorally administered HB-201, and intravenously administered HB-202 by assessing drug limiting toxicities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II Dose Expansion: Number of participants with preliminary antitumor activity based on objective response rate and disease control rate.</measure>
    <time_frame>Until progression, (estimated up to 30-months)</time_frame>
    <description>Assess the preliminary antitumor activity of dosage regimens of HB-201 and HB-202 using Response Evaluation Criteria in Solid Tumors (RECIST) and immune Response Evaluation Criteria in Solid Tumors (iRECIST) to determine objective response rate and disease control rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I Dose Escalation: Number of participants with adverse events (type, frequency, severity).</measure>
    <time_frame>From informed consent through 30 days after last dose.</time_frame>
    <description>Assess the safety and tolerability of dosage regimens of HB-201 and HB-202 by monitoring the type, frequency, and severity of AEs and SAEs by monitoring the type, frequency, and severity of AEs and SAEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I Dose Escalation: Number of participants with preliminary antitumor activity based on objective response rate and disease control rate.</measure>
    <time_frame>Until progression, (estimated up to 30-months)</time_frame>
    <description>Assess the preliminary antitumor activity of dosage regimens of HB-201 and HB-202 using RECIST and iRECIST to determine objective response rate and disease control rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II Dose Expansion: Number of participants with confirmed duration of preliminary antitumor activity.</measure>
    <time_frame>Up to 30-months (until progression)</time_frame>
    <description>Confirm duration of preliminary antitumor activity of dosage regimens of HB-201 and HB-202, using RECIST and iRECIST to determine overall survival, progression-free survival, and duration of response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II Dose Expansion: Number of participants with adverse events (type, frequency, severity).</measure>
    <time_frame>From informed consent through 30 days after last dose</time_frame>
    <description>Assess the safety and tolerability of dosage regimens of HB-201 and HB-202 by monitoring the type, frequency, and severity of AEs and SAEs.</description>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>HPV-Related Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Ph I, Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph I, Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HPV 16+ cancers with a safe and accessible tumor site amenable for IT administration who had tumor progression or recurrence on standard of care therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph I, Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph I, Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HPV 16+ cancers with a safe and accessible tumor site amenable for IT administration who had tumor progression or recurrence on standard of care therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph II, Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph II, Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care and are eligible to receive immune checkpoint inhibitor as part of standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph II, Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HPV 16+ cancers with a safe and accessible tumor site amenable for IT administration who had tumor progression or recurrence on standard of care therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph II, Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph II, Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care and are eligible to receive immune checkpoint inhibitor as part of standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph II, Group F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HPV 16+ cancers with a safe and accessible tumor site amenable for IT administration who had tumor progression or recurrence on standard of care therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph I, Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph I, Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph I, sub-study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HB-201 intravenous administration.</intervention_name>
    <description>Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort).</description>
    <arm_group_label>Ph I, Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HB-201 intratumoral administration for first dose, followed by HB-201 intravenous administration for subsequent doses.</intervention_name>
    <description>Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort)</description>
    <arm_group_label>Ph I, Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HB-202 intravenous administration alternating with HB-201 intravenous administration.</intervention_name>
    <description>Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort).</description>
    <arm_group_label>Ph I, Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HB-201 intratumoral administration for first dose; followed by HB-202 intravenous administration alternating with HB-201 intravenous administration for subsequent doses.</intervention_name>
    <description>Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort)</description>
    <arm_group_label>Ph I, Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HB-201 intravenous administration at recommended phase II dose and determined schedule.</intervention_name>
    <description>Dose Expansion</description>
    <arm_group_label>Ph II, Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HB-201 intravenous administration at recommended phase II dose and determined schedule + immune checkpoint inhibitor per standard of care.</intervention_name>
    <description>Dose Expansion</description>
    <arm_group_label>Ph II, Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HB-201 intratumoral administration for first dose followed by HB-201 intravenous administration for subsequent doses at recommended phase II dose and determined schedule.</intervention_name>
    <description>Dose Expansion</description>
    <arm_group_label>Ph II, Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HB-202 intravenous administration alternating with HB-201 intravenous administration at recommended phase II doses and determined schedule.</intervention_name>
    <description>Dose Expansion</description>
    <arm_group_label>Ph II, Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HB-201 intratumoral administration for first dose; followed by HB-202 intravenous administration alternating with HB-201 intravenous administration for subsequent doses at recommended phase II dose.</intervention_name>
    <description>Dose Expansion</description>
    <arm_group_label>Ph II, Group F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HB-202 intravenous administration alternating with HB-201 intravenous administration at recommended phase II doses and determined schedule + immune checkpoint inhibitor.</intervention_name>
    <description>Dose Expansion</description>
    <arm_group_label>Ph II, Group E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HB-201 intravenous administration for a limited number of dose administration.</intervention_name>
    <description>Dose/Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort)</description>
    <arm_group_label>Ph I, Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HB-202 intravenous administration alternating with HB-201 intravenous administration for a limited number of dose administration</intervention_name>
    <description>Dose/Schedule determined by 3+3 dose escalation</description>
    <arm_group_label>Ph I, Group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)</intervention_name>
    <description>Dose escalation; 10 patients</description>
    <arm_group_label>Ph I, sub-study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        All Patients:&#xD;
&#xD;
          -  Documentation of confirmed HPV 16+ cancer via genotype testing.&#xD;
&#xD;
          -  ≥ 1 measurable lesion by imaging for tumor response following RECIST&#xD;
&#xD;
          -  ECOG performance status of 0 to 1.&#xD;
&#xD;
          -  Prior curative radiation therapy and prior focal palliative completed per&#xD;
             protocol-specified wash-out windows.&#xD;
&#xD;
          -  Screening laboratory values must meet protocol-specified criteria.&#xD;
&#xD;
          -  Able to provide tumor tissue following last treatment, unless otherwise agreed.&#xD;
&#xD;
        Treatment Group 1, Group 3, Group 5, Group 6, Group A, or Group D:&#xD;
&#xD;
          -  Documentation of confirmed head and neck squamous cell carcinoma.&#xD;
&#xD;
          -  Tumor progression or recurrence on standard of care therapy, including ≥ 1 systemic&#xD;
             therapy.&#xD;
&#xD;
        Treatment Group 2, Group 4, Group C, or Group F:&#xD;
&#xD;
        • Tumor progression or recurrence on standard of care therapy, including ≥ 1 systemic&#xD;
        therapy.&#xD;
&#xD;
        Treatment Group B or Group E:&#xD;
&#xD;
          -  Documentation of confirmed head and neck squamous cell carcinoma.&#xD;
&#xD;
          -  Eligible, per standard of care, to receive immune checkpoint inhibitor.&#xD;
&#xD;
        Anal Cancer Cohort:&#xD;
&#xD;
          -  Documentation of confirmed HPV 16+ locally advanced or metastatic SCC of anal canal.&#xD;
&#xD;
          -  Tumor progression or recurrence on standard of care therapy, including ≥1 systemic&#xD;
             therapy.&#xD;
&#xD;
        Imaging Sub-Study (for specific participants at Memorial Sloan Kettering Cancer Center&#xD;
        only):&#xD;
&#xD;
          -  Meeting requirements of inclusion criteria for Treatment Group 1 or Group 3.&#xD;
&#xD;
          -  At least 1 non-irradiated measurable lesion documented through imaging.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All patients:&#xD;
&#xD;
          -  Untreated and/or symptomatic metastatic central nervous system disease, unless&#xD;
             protocol-defined criteria is met.&#xD;
&#xD;
          -  Any serious or uncontrolled medical disorder that, in the opinion of the Investigator,&#xD;
             may increase the risk associated with study participation / treatment administration.&#xD;
&#xD;
          -  Concurrent malignancy that is clinically significant or requires active intervention,&#xD;
             unless protocol-defined criteria is met.&#xD;
&#xD;
          -  Active, known or suspected, autoimmune or inflammatory disorders requiring&#xD;
             immunosuppressive therapy.&#xD;
&#xD;
          -  Any toxicities attributed to systemic prior anticancer therapy o that have not&#xD;
             resolved to Grade 1 or baseline prior to the first administration of study drug,&#xD;
             unless protocol-defined criteria is met.&#xD;
&#xD;
          -  Not meeting the protocol-specified washout periods for prohibited medications.&#xD;
&#xD;
          -  Prior anaphylactic or other severe reaction to human immunoglobulin or antibody&#xD;
             formulation administration.&#xD;
&#xD;
          -  Positive hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody,&#xD;
             indicating acute or chronic infection.&#xD;
&#xD;
          -  Known history of acquired immunodeficiency syndrome.&#xD;
&#xD;
        For patients in Groups B or E and certain backfill cohorts:&#xD;
&#xD;
          -  History of severe hypersensitivity reaction to or other contraindication to receiving&#xD;
             immune checkpoint inhibitor.&#xD;
&#xD;
          -  Allogenic tissue/solid organ transplant.&#xD;
&#xD;
          -  History of/Presently having non-infectious pneumonitis requiring treatment.&#xD;
&#xD;
        Imaging Sub-Study (for specific participants at Memorial Sloan Kettering Cancer Center&#xD;
        only):&#xD;
&#xD;
          -  Having splenic disorders or prior splenectomy, and can compromise protocol objectives&#xD;
             per Investigator and/or Sponsor.&#xD;
&#xD;
          -  Meeting requirements of exclusion criteria for Treatment Group 1 or Group 3&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Hookipa Biotech GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>General Hookipa contact</last_name>
    <phone>+43 1 890 6360</phone>
    <email>office@hookipabiotech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hookipa Backup Contact</last_name>
    <phone>+1 332 207 4590</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>O'Neal Comprehensive Cancer Center at UAB</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley M Anderson</last_name>
      <phone>205-966-0882</phone>
      <email>ashau82@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Lisle Nabel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Molzen</last_name>
      <email>Eileen.Molzen@bannerhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Tina Schaffner</last_name>
      <email>Tina.Schaffner@bannerhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jiaxin Niu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Nieva, MD</last_name>
      <phone>323-865-3111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reisy Guesdes</last_name>
      <phone>305-243-8807</phone>
      <email>rxg957@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Agustin Pimentel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Pearson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KUCC Nurse Navigator</last_name>
      <phone>913-588-3671</phone>
      <email>kucc_navigation@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Prakash Neupane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karie Gignac</last_name>
      <phone>313-916-7453</phone>
      <email>kgignac1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Ding Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nate Beck</last_name>
      <email>nbeck@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas Adkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore-Einstein Center for Cancer Care</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Ghalib</last_name>
      <phone>718-405-8515</phone>
      <email>mhghalib@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Sanjay Goel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Libby Warner</last_name>
      <email>warnere@mskcc.org</email>
    </contact>
    <contact_backup>
      <last_name>Jamie Walters</last_name>
      <email>waltersj@mskcc.org</email>
    </contact_backup>
    <investigator>
      <last_name>David Pfister, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Posner, MD</last_name>
      <phone>212-659-5461</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Richardson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Pomeroy</last_name>
      <email>Melissa.Pomeroy@providence.org</email>
    </contact>
    <investigator>
      <last_name>Rom Leidner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital System University Medical Center (ITOR)</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Johnson</last_name>
      <phone>864-455-3735</phone>
    </contact>
    <contact_backup>
      <last_name>Fiona Davidson</last_name>
      <phone>864-455-3737</phone>
    </contact_backup>
    <investigator>
      <last_name>Ki Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siquing Fu, MD</last_name>
      <email>siqingfu@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital and Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart Wong, MD</last_name>
      <phone>414-805-8900</phone>
      <email>CCCTO@mcw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2019</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>TheraT®</keyword>
  <keyword>E7E6</keyword>
  <keyword>HPV 16 E7E6</keyword>
  <keyword>HNSCC</keyword>
  <keyword>HPV 16+ head and neck squamous cell cancer</keyword>
  <keyword>Oropharyngeal cancer</keyword>
  <keyword>Penile cancer</keyword>
  <keyword>Anal cancer</keyword>
  <keyword>Cervical cancer</keyword>
  <keyword>Vaginal cancer</keyword>
  <keyword>Vulvar cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

